Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
about
Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patientsT cell regulation of p62(dok) (Dok1) association with Crk-LThe product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent mannerRole of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesisA fusion protein formed by L-myc and a novel gene in SCLCTLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.Tyrosine phosphorylation of p62(Dok) induced by cell adhesion and insulin: possible role in cell migrationThe BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B proteinA direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinaseLessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemiaThe PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activityMolecular cloning of Ian4: a BCR/ABL-induced gene that encodes an outer membrane mitochondrial protein with GTP-binding activityAMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLDepletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoformsDiscovery of the Philadelphia chromosome: a personal perspectiveAssociation of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)The Philadelphia chromosome in leukemogenesisNew Developments in Chronic Myeloid Leukemia: Implications for TherapyChronic myeloid leukemia: reminiscences and dreamsClinical significance of microRNAs in chronic and acute human leukemiaManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentStructural Basis of Targeting the Exportin CRM1 in CancerThe Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia TherapyCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaClonal evolution in hematological malignancies and therapeutic implicationsThe structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)CRKL binding to BCR-ABL and BCR-ABL transformationCharacterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathwayPTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemiaInhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatmentInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsAHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cellsp62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl)ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalingsUrsolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisInteractions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
P2860
Q22254246-CD2A199C-4D35-4B39-91A9-9BACA3EDC46FQ24291680-5473A029-EF3C-4BAB-8E67-A2012A291159Q24310761-7D4AE250-7BDC-43F3-BD59-9CED6D7D28DBQ24317141-4BD16208-30A9-4BAE-8369-ABA396EFBAB9Q24317183-27719673-713C-4B8B-9BEC-C19FD99D916FQ24533281-912AAE7C-A3C9-4A6A-9604-73241F1B2C37Q24534026-E093F353-CFAF-43D2-B07F-6CB435650042Q24553320-839742A8-6A71-4D05-BC4F-3280DA1B1ED4Q24563301-063EDACF-176E-4145-BE1B-D68283EA8801Q24599829-41803E99-6D2F-4FB9-8E33-8511B8345612Q24606662-5554FB59-8B05-4A35-B4DF-78E93BDC667EQ24613207-F6B9FE2C-9033-4467-A685-F952AD1D72E5Q24651465-6649F874-E66F-403A-B3BE-038CC9D90D18Q24658292-9932E7EA-A918-4133-AB8E-F29F35D6CD00Q24683696-68F799DA-A1FB-43E6-AFBD-4C71629C97F9Q24797667-984E43C5-7449-4E9E-BBAD-1B9C838E9C1AQ26745531-3786C5B0-7255-4F1D-BE81-E759700B827DQ26745669-2448299B-23B1-4FF4-A6D1-48C7DB4281E9Q26748769-C763C350-B3DB-4995-AF0D-8E8E1A7CF284Q26749533-9C4750BB-BBC1-4026-BC4A-168F40257B9FQ26766299-53D6FAF5-1AF2-4667-81FA-F28E831FD44AQ26781513-D2F5E1FD-2DAF-4599-B357-F86F4B701F79Q26799596-FE764BA0-F81C-45AD-97F8-9BA4792AB8C1Q27025242-BD9D888E-E2DB-4992-B0D9-F2C6EF76DC9BQ27027655-45E055D4-BFE7-4F96-B828-40D30C4CB7D7Q27653890-43181258-915F-45B4-A7F8-39883B9F0ABAQ28140785-07D3D1B1-3894-4D5A-9F63-688510B66B03Q28206167-FED7A8E4-FBA0-45D0-97FF-DB76DCDC05C1Q28540547-90E19190-E8DD-4620-8995-42DC6516FF7CQ28541451-C6180E32-854B-471E-B81A-ADA8EF1C4F0AQ28545195-8713B18E-E118-40C7-B789-AD55F1C14020Q28586026-ED6CF4DC-7C5A-4BDA-95FE-6D40996E90BFQ28587732-426C9BFD-EC12-4DF9-B281-828C073F8532Q28609080-843F1E77-A9F6-4C0F-84EF-1E78D59AC21EQ28741022-B5E1F7E0-BE3C-4672-807B-FCD27DFF3BF2Q28830045-0A0FC4E8-498C-4AEC-A903-826E48815B70Q30010179-308A2B74-7750-43D7-97F9-47790A410C6EQ30175784-67FC447B-0200-44DF-802B-5147C448DA56Q30175971-C3FE0191-104F-4D2D-9C50-15417A86FC98Q30176501-FB7DEB13-5CEE-4B2C-B220-97BD05308C7F
P2860
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
@en
type
label
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
@en
prefLabel
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
@en
P2093
P356
P1433
P1476
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
@en
P2093
A M Pendergast
P304
P356
10.1126/SCIENCE.2408149
P407
P577
1990-03-01T00:00:00Z